Virus associated Carcinogenesis Mechanism Analysis Service
Creative Biolabs offers a modular approach to dissecting the molecular mechanisms underpinning viral oncogenesis. We provide actionable insights and quantitative data essential for developing targeted antiviral and anti-tumor therapies. Our services transform complex viral biology—including host-virus protein-protein interactions, viral DNA integration, and virus-induced immune evasion—into therapeutic opportunities. By focusing on the core mechanisms of viral transformation, we empower clients to design effective strategies that target both the virus and the resulting malignancy, accelerating the development of novel cancer treatments.
Background What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
The Mechanisms: How Viruses Rewire the Cell
Viral oncogenesis involves several molecular mechanisms: Genomic integration and instability, where retroviruses and DNA viruses insert genetic material (insertional mutagenesis) into host loci like TERT and MLL4, often driven by reactive oxygen species (ROS)-induced double-strand breaks (DSBs). Epigenetic "hit-and-run" involves viruses like Epstein-Barr virus (EBV) and HPV recruiting host enzymes to hypermethylate tumor suppressor promoters or alter histone landscapes to silence immune genes. Metabolic reprogramming (Warburg effect) sees viruses hijack host enzymes to drive aerobic glycolysis and nucleotide synthesis. Chronic inflammation and oxidative stress from persistent infection (HCV) generate ROS, which directly damages DNA and fuels viral integration and somatic mutation.
Strategic Medical and Research Solutions
High-Resolution Integration Mapping
We use long-read sequencing to accurately determine the location and structure of viral integration sites (VIS), resolving complex events that link genomic instability directly to oncogenic drivers like TERT and CCNE1. This precision identifies novel therapeutic targets near the insertion point.
Functional Oncoprotein Characterization
We analyze the binding partners and functional consequences of critical viral oncoproteins. Our methods map their direct disruption of host tumor suppressors (e.g., p53, pRB) and crucial growth control pathways, providing the mode-of-action (MoA) evidence required for drug design.
Immune Evasion Profiling
We provide quantitative data on how the target virus manipulates immune surveillance, specifically assessing the downregulation of MHC expression and the suppression of the interferon (IFN) pathway via viral antagonists. Understanding these escape tactics is paramount for developing effective immunotherapies.
Therapeutic Target Validation
Our analysis identifies metabolic and signaling vulnerabilities of virus-transformed cells, such as the Warburg effect or dependence on a host factor identified via high-throughput CRISPR/Cas9 screening.
Ready to transform mechanistic complexity into a clear therapeutic path? Contact Creative Biolabs today to schedule a confidential discussion about your specific viral oncology targets.
Workflow
The workflow for service is structured as a five-phase, integrated pipeline designed for maximal accuracy and data interpretability.
Publication
This comprehensive review marks the 60th anniversary of the first oncovirus (EBV) discovery. It details how seven major viruses (e.g., HPV, HBV, EBV) cause ~8% of global cancers by hijacking cellular processes, inducing genomic instability, and evading immunity. The article systematically explores these mechanisms across specific cancers and evaluates current strategies—from vaccines and antivirals to immunotherapy and cell therapy—providing a crucial resource for advancing the prevention and treatment of virus-driven malignancies.
Fig.1 Key milestones in the history of viral oncogenesis research. 1
Why Choose Us?
Creative Biolabs is the industry leader in viral oncogenesis research, leveraging 20+ years of expertise and single-cell resolution to provide crucial insights that standard short-read facilities miss. Our integrated multi-omics platform is one of the few offering simultaneous analysis of genomics, proteomics, and metabolomics from the same sample set, ensuring a comprehensive understanding of the viral MoA. We focus on actionable targets that link the viral mechanism directly to a therapeutically druggable solution, accelerating your path to application. Furthermore, our cutting-edge comparative analysis benchmarks mechanisms against a wide range of known pathogens, highlighting convergent pathways for resilient therapeutic design.
Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
How does this service handle viruses that don't integrate their genome, like HCV?
For non-integrating viruses (HCV), we use a multi-pronged approach: functional assays for non-structural proteins (e.g., NS5A/β-catenin) and tumor microenvironment (TME) analysis of inflammation/oxidative stress.
Is your long-read sequencing platform truly better than standard short-read sequencing for integration site mapping?
Yes. Our third-generation sequencing provides reads long enough to span the entire virus-host junction, resolving complex VIS with single-nucleotide resolution, overcoming the limitations of short-read sequencing.
What are the typical starting materials required, and how do you ensure their quality for multi-omics analysis?
We accept fresh frozen tumor tissue, cell lines, or viral isolates. All samples undergo rigorous quality control (QC) (spectrophotometry, RIN score check) to ensure high-fidelity data for downstream multi-omics analysis.
Customer Review
-
Target Validation
Their functional assays confirmed that EBNA1 was disrupting p53 stability in our cell lines, providing a clear rationale for our small molecule inhibitor design. We wouldn't have moved forward without this level of mechanistic clarity. – Ana*Brth
-
Technical Superiority
Standard sequencing was inconclusive, but Creative Biolabs provided full-length, structural variants of the integration events. This technical superiority allowed us to precisely measure copy number variation and genomic instability across our patient cohort. – Mk*Res
Related Services
To achieve your drug development goals, Creative Biolabs recommends these complementary services, which often follow the mechanistic analysis:
Viability and Biodistribution Studies
Creative Biolabs offers pre-clinical viability and biodistribution studies for cell/gene therapies. Services include cell viability detection and GLP-compliant biodistribution tracking using labeled cells in appropriate animal models.
Learn More →
T Cell Engineering Service
Creative Biolabs offers comprehensive, one-stop T cell engineering services, including CAR-T therapy, TCR therapy, and γδ T-APC engineering. We customize solutions using electroporation, viral transduction, and gene editing technologies.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs offers the industry's most comprehensive and advanced virus-associated carcinogenesis mechanism analysis service. By merging deep virology expertise with cutting-edge multi-omics technologies, we systematically dismantle the complex mechanisms by which viruses rewire host cells, transforming biological complexity into actionable therapeutic targets with unparalleled speed and precision.
We invite you to reach out to our team of experts to discuss how our service can be precisely tailored to the needs of your current project, ensuring a clear path from discovery to application.
Reference
-
Xiao, Qing, et al. "Viral oncogenesis in cancer: from mechanisms to therapeutics." Signal Transduction and Targeted Therapy 10.1 (2025): 151. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41392-025-02197-9
For Research Use Only | Not For Clinical Use
Download our brochure